Industry news
Horizon Pharma plc to acquire DepoMed Inc. for $3 billion
Horizon Pharma plc announced a proposal to acquire all outstanding shares of Depomed, Inc. for approximately $3.0 billion. DepoMed products in the USA include Nucynta ER for pain control, Cambria for migraine, PecFent for cancer pain and the company holds world rights for Gralise and Zipsor for pain control as well as non-North American rights for Glumetza for diabetes. This is a contested bid.